Business
Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028
2025 Full-year results and business update Transgene Continues Progressto Reshape Early-Stage Cancer Treatmentthrough Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028 TG4050, Transgene’s first INTV, demonstrated durable clinical outcomes in resected head and neck squamous cell carcinoma (HNSCC) and potential to prevent cancer relapseRandomization of Phase 2 patients nearly completed -Disease-free survival1 from evaluable patients in the Phase
About this update from Transgene Sa
[{"type":"image","alt":"Transgene S.A.","displaySize":"","headline":null,"caption":"Transgene S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":61,"url":"https://media.zenfs.com/en/globenewswire.com/c8cdd55e9740420b0ba23689bb358d87"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GkcYa2vpmQuYJOEXoBAQCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg1/https://media.zenfs.com/en/globenewswire.com/c8cdd55e9740420b0ba23689bb358d87","width":300,"height":61}},"lazy":false},{"type":"text","content":"2025 Full-year results and business update","length":42,"tagName":"p"},{"type":"text","content":"Transgene Continues Progressto Reshape Early-Stage Cancer Treatmentthrough Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028 ","length":184,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"TG4050, Transgene’s first INTV, demonstrated durable clinical outcomes in resected head and neck squamous cell carcinoma (HNSCC) and potential to prevent cancer relapseRandomization of Phase 2 patients nearly completed -Disease-free survival1 from evaluable patients in the Phase 2 part of the Phase 1/2 study expected 2 years after completion of randomization","length":366,"tagName":"p"},{"type":"text","content":"myvac® platform: new Phase 1 trial in a second indication in operable solid tumors planned to start in 2026 ","length":112,"tagName":"p"},{"type":"text","content":"BT-001: Phase 1 results in patients with advanced refractory tumors support further clinical development","length":109,"tagName":"p"},{"type":"text","content":"€111.9 million in cash available as of December 31, 2025 – business funded until early 2028","length":96,"tagName":"p"},{"type":"text","content":"Conference call scheduled today at 6 p.m. CET (in English). See details below.","length":78,"tagName":"p"},{"type":"text","content":"Strasbourg, France, March 24, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its full-year financial results for the year ended December 31, 2025, and provides an update on its lead INTV asset TG4050 developed from its myvac® platform together with upcoming plans for 2026.","length":408,"tagNam...